The Ninth Annual meeting of the Urological Society of Australasia recently took place in Newcastle, New South Wales, Australia. Selected highlights of the meeting are reviewed.
Open prostatectomy
Dr Alex Zlotta (Brussels, Belgium) discussed the current role of open prostatectomy for benign prostatic hyperplasia (BPH). Traditionally, this technique has been reserved for larger prostates, but it is frequently used for smaller prostates in certain centres. Although there are limited indications for the open procedure, it should be noted that it is associated with an appreciably lower reintervention rate than transurethral resection of the prostate (TURP). The Mullin procedure, a modification of the Gregoir technique from the 1950s, is used in Belgium. Data on a series of patients treated during 2003 indicate that prostate size resected was 37-153 g during a mean operating time of 71 min (range: 35-120 min). On average, 50 g (range 30-119 g) of tissue was enucleated with a mean blood loss of 421 ml. Other statistics on this series were mean catheterisation period 3 days and mean hospitalisation 5.1 days. With regard to minor complications, 4% of patients had retention, 8% a urinary tract infection and 6% a wound infection. One pulmonary embolism occurred at 2 days post surgery, which was not surprising considering the advanced age of patients treated. Dr Zlotta concluded that open prostatectomy is a safe and effective procedure, with short catheterisation and hospitalisation periods and a long-term efficacy superior to TURP.
TUIP, TURP and bipolar technology
Dr Chris Love (Melbourne, Australia) discussed the advantages of the bipolar technique using the Gyrust equipment for enucleation of the prostate. TURP relies on monopolar electrocautery and can give rise to TUR syndrome through fluid absorption, as well as secondary haemorrhage. With the bipolar method, the active and return electrode are in the same device, around which a vapour pocket is generated. Actually, cutting of tissues is carried out by the vapour in two directions, albeit at a slower rate than with TURP. Comparative studies suggest that catheter removal can occur earlier in patients treated with the bipolar method and there is also a lower rate of adverse events (blood loss, TUR syndrome). Other advantages are that the device can be used in patients with pacemakers and there is a short learning curve.
Transurethral ethanol ablation of the prostate (TEAP)
Dr Henry Woo (Sydney, Australia) reported on the use of ethanol to ablate prostate tissue through a perineal approach. Introduced 20 y ago, it was associated with considerable side effects. The mechanism of tissue destruction is through cell membrane damage, denaturation of protein, and vascular occlusion and ischaemia. A transurethral approach has been developed in which ethanol is delivered by a needle placed at a 451 angle to the cystoscope. The volume of ethanol is based on the size of the prostate, with 10-15 g usually delivered during this 5 min procedure. Postoperative catheterisation is usually for 2-3 days. Few data from randomised controlled trails (RCTs) are available. One study involving 60 patients randomised to TEAP or TURP indicated similar improvements in International Prostate Symptom Score (IPSS) and quality of life (QOL) with both treatments. Collective data on 2000 patients treated worldwide indicate the following adverse event profile: irritative lower urinary tract symptoms (LUTS): 13%; urinary retention: 17%; transient haematuria: 13%; erectile dysfunction o1%. Dr Woo concluded that TEAP is an evolving treatment option for BPH, with its short operative time it could be considered for patients with significant comorbidity; however, RCTs are still required to confirm its efficacy.
Brachytherapy following TURP
The impact of TURP on the morbidity following 1-125 brachytherapy was reported (Moon et al, Melbourne, Australia). Of the 143 patients treated with brachytherapy, 21 had previously undergone a TURP procedure; 15 of these were a median lobe resection/incision. Prior TURP did not interfere with seed implantation and no variation in dosimetry or number of seeds implanted was reported in the TURP group compared with the non-TURP group of patients. The rate of acute urinary retention postimplant was not significantly different between the two groups, nor was IPSS at 3 or 6 months. A similar level of overall complications was reported by both groups at a median follow-up of 19 months. Dr Moon concluded that limited prostate resection or incision to alleviate obstruction prior to seed implant did not appear to increase the risk of complications.
Sural nerve grafting at radical prostatectomy
The anatomy of the neurovascular bundle has been studied in 12 adult male cadavers, together with its relationship to surrounding pelvic structures (Costello and Brooks, Victoria, Australia). Identified was the presence of innervation to the rectum, prostate and levator ani musculature within the neurovascular bundle, not previously reported. The authors of the report concluded that the terms neurovascular bundle and cavernous nerves should not be used synonymously, the latter being inferior nerves from the pelvic plexus. They also suggested that the current practice of anastomosing sural nerve to any identifiable neural structure was inappropriate.
Laparoscopic radical prostatectomy: the Australian experience
Kovac and Vass (Wollongong, Australia) reported on the use of laparoscopic radical prostatectomy in 37 patients aged 50-73 y in Australia; the first 12 cases were transperitoneal and the remainder, retroperitoneal. Of the cases, six were clinical T2 and 20 T1C; mean prostatespecific antigen (PSA) was 11 ng/ml (range: 1.4-64 ng/ ml). Other statistics included: mean operation time 4.5 h; mean blood loss 375 ml; and mean hospitalisation 5.7 days. No transfusions were required or any conversion to the open procedure. Overall, negative margins were achieved in 81% of patients and significant incontinence was reported in only one patient. Pathology results indicated that prostate cancer was Gleason 6 in six patients, 7 in 27 patients, and 8 and 9 in two each. With regard to complications associated with this type of procedure, the following were reported: one pelvic abscess; one rectal injury; two epigastric artery injuries; and one wound infection (drain site).
Clinical trial guidelines for patients with rising PSA
The Prostate-Specific Antigen Working Group has published guidelines for patients in clinical trials who have relapsed prostate cancer (Scher HI et al, J Clin Oncol 2004; 22: 537-556) . The Group focused on men with systemic (nonlocalized) recurrence and a defined risk of developing clinically detectable metastases. Discussed were models to define systemic vs local recurrence and risk of metastatic progression. It was recommended that study reports include details of the number of patients who achieve a specific PSA-based outcome, the number who remain enrolled onto the trial, as well as the number who came off study at different time points. It was also recommended that the term 'PSA response' be abandoned. With regard to drug development, it was recommended that at the minimum with an individual drug treatment there should be no rise in PSA in a defined proportion of patients for a specified period of time. Drugs that do not produce this effect should only be tested in combination. The group stated that the preferred end point of clinical benefit is PSA-specific survival, with time to development of metastatic disease as an alternative.
Prostate cancers detected at low PSA levels Horninger et al (Prostate 2004; 58: 232-237) report that small prostate cancers with low PSA levels and low tumour volumes exhibit all of the features of prostate cancers with higher tumour volumes and show the characteristics of malignant cancers. The group studied prostate cancers in patients with low PSA levels in terms of heterogeneity, clinical significance, multifocality, and tumour biology including ploidy and proliferation index. It was shown that Gleason score of needle biopsy specimens failed to predict the Gleason score of the radical prostatectomy specimen in nearly 40% of these patients. Of the patients with low PSA levels, 65% showed multifocal lesions and 36% exhibited tetraploid DNA distribution; more than 50% of tetraploid tumours were found in patients with tumour volumes of less than 0.5 ml. In addition, ploidy correlated with the Ki-67 proliferation index, but not with tumour volume.
Impact of EBRT and radical prostatectomy on HRQOL van Andel et al (Prostate 2004; 58: 354-365 ) have compared the impact of external beam radiotherapy (EBRT) and radical prostatectomy on general and disease-specific health-related quality of life (HRQOL) in patients with localised prostate cancer. A total of 138 patients completed a validated HRQOL instrument before and 12 months after the treatment. Results indicated that patients treated with radical prostatectomy had a significantly greater improvement in their emotional function, while they reported more incontinence and a worse sexual function. The improvement in the overall HRQOL of EBRT patients was significantly greater, while the changes in the gastrointestinal function of these patients were significantly worse. Only the differences with respect to incontinence could be attributed to the treatment itself. Baseline scores were the primary influence on the majority of changes in HRQL scores; the influence of age and socioeconomic status was limited.
Underutilisation of DRE in prostate cancer screening
Despite the American Cancer Society and American Urology Association recommending prostate cancer screening with both digital rectal examination (DRE) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
Stephenson AJ et al (JAMA 2004; 291: 1325 -1332 report on the use of salvage radiation in patients failing radical prostatectomy in an attempt to identify patients who might benefit from this approach. A retrospective review was conducted of 501 patients from five centres in the US who received salvage radiotherapy between June 1987 and November 2002 for PSA increase after radical prostatectomy. Disease progression after salvage radiotherapy was defined as a serum PSA value Z0.1 ng/ml above the postradiotherapy PSA nadir confirmed by a second PSA measurement that was higher than the first by any amount, by a continued increase in PSA level after treatment or by the initiation of androgen deprivation therapy after treatment.
Results showed that over a median follow-up of 45 months, 250 patients (50%) experienced disease progression after treatment, 49 (10%) developed distant metastases, 20 (4%) died from prostate cancer and 21 (4%) died from other or unknown causes. The 4-y progression-free probability (PFP) was 45%. Multivariable analysis indicated that predictors of progression were Gleason score of 8-10; preradiotherapy PSA level 42.0 ng/ml; negative surgical margins; PSA doubling time (PSADT) of r10 months; and seminal vesicle invasion. Patients with no adverse features had a 4-y PFP of 77%. When treatment was given for early recurrence (PSA level r2.0 ng/ml), patients with Gleason score 4-7 and a rapid PSADT had a 4-y PFP of 64 and 22% when the surgical margins were positive and negative, respectively. Patients with Gleason score 8-10, positive margins and receiving early salvage radiotherapy had a 4-y PFP of 81% when the PSADT was longer than 10 months and of 37% when the PSADT was r10 months. It was concluded that selected patients with high-grade disease and/or a rapid PSADT who were considered to be at risk of progressive metastatic disease may achieve a durable response to salvage radiotherapy.
Survival of patients with hormone refractory prostate cancer
Oefelein MG et al (J Urol 2004; 171: 1525-1528) have published a report on survival in patients with hormone refractory prostate cancer, which suggests that survival time is actually longer than previously thought. The report focused on 254 patients with prostate cancer on androgen deprivation therapy. Hormone refractory prostate cancer was defined as the first in a series of PSA elevations despite castrate levels of testosterone. The duration of survival in the hormone refractory phase was calculated from the date of the first PSA elevation to the date of death. Results showed that median survival after hormone refractory prostate cancer developed in patients initially staged with and without skeletal metastasis was 40 and 68 months, respectively. Variables associated with longer survival were lower nadir PSA, younger age, higher pretreatment testosterone, no history of obstructive uropathy, no history of tobacco use (past or current) and lower alkaline phosphatase. The authors suggest that the discrepancies between the historically reported 12-to 18-month duration of survival in this patient group and the current observations may be due to delayed enrolment in clinical trials from which most survival data are derived, PSA lead time in staging and improved supportive care.
Proenzyme forms of PSA and prostate cancer detection
In an attempt to improve diagnostic markers for prostate cancer, immunoassays have been developed to measure specific proPSA forms containing propeptides of 2, 4 and 7 amino acids: (À2)proPSA, (À4)proPSA and (À7)proP-7)proPSA, respectively (Mikolajczyk et al, Clin Chem 2004, March 30) . Serum samples from patients with prostate cancer or BPH were tested for specificity and sensitivity. Results indicated that the proPSA forms had quantification limits of 0.015-0.025 mg/l in serum, with cross-reactivities o1% with PSA. The proPSA comprised a median of 33% of the free PSA (fPSA) in cancer and 25% in noncancer sera (Po0.0001). One-third (33%) of cancer samples had 440% proPSA, compared with only 8% of noncancer samples (Po0.0001). In men with cancer and 425% fPSA, the (À2)proPSA had an AUC of 0.77, with 90% sensitivity and 36% specificity at 0.04 mg/l. It was concluded that percentage proPSA provided a better cancer detection rate in the 4-10 mg/l range than percent fPSA and complexed PSA. Importantly, in men whose serum had more than 25% fPSA, (À2)proPSA improved prostate cancer detection.
Updated meta-analysis of Serenoa repens extract trials in BPH Long-term morbidity and mortality of transurethral prostatectomy: A 10-year follow-up A study has been conducted looking at long-term complication and reoperation rates in 1211 patients undergoing TURP for symptomatic BPH between 1988 and 1991 (Varkarakis et al, Prostate 2004 58: 248-251) . Follow-up of at least 10 y had been conducted in this patient group; follow-up data were available on 577 (47.6%) of the patients. Long-term complications as well as reoperation rates were evaluated on the basis of a patient questionnaire or a physician interview. Analysis showed that a repeat operation had to be performed in 35 (6%) patients: for bladder neck contracture in 14 (2.4%) patients; for BPH obstruction in 11 (1.9%) patients; and for urethral strictures in 10 (1.7%) patients. It was concluded that the gold standard for BPH therapy is still TURP due to its low reoperation rates. Late complications requiring intervention may occur as late as 10 y postsurgery and consequently follow-up should be continued in these patients.
